Resultado da Busca
25 de out. de 2022 · Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomised trials.
15 de jul. de 2016 · Of all patients with metastatic cancer, the most common sites of metastasis were the liver (70% in colon cancer/70% in rectal cancer) and the thorax (32%/47%). In colon cancer, the third most common site was the peritoneum (21%) whereas in rectal cancer it was the bone (12%).
- Matias Riihimäki, Matias Riihimäki, Akseli Hemminki, Jan Sundquist, Kari Hemminki, Kari Hemminki
- 10.1038/srep29765
- 2016
- Sci Rep. 2016; 6: 29765.
17 de out. de 2022 · PDF. Abstract. Purpose. To develop recommendations for treatment of patients with metastatic colorectal cancer (mCRC). Methods. ASCO convened an Expert Panel to conduct a systematic review of relevant studies and develop recommendations for clinical practice. Results.
25 de out. de 2022 · Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up5 A. Cervantes1,2, R. Adam3, S. Roselló1,2, D. Arnold4, N. Normanno5, J. Taïeb6,7, J. Seligmann8, T. De Baere9,10,11, P. Osterlund12,13, T. Yoshino14 & E. Martinelli15, on behalf of the ESMO Guidelines Committee*
19 de set. de 2019 · The most common sites of metastasis are the liver and the peritoneum. Peritoneal carcinomatosis is often considered the end stage of the disease after the tumor has spread to the liver. However, almost half of CRC patients with peritoneal carcinomatosis do not present with liver metastasis.
- E. Pretzsch, F. Bösch, J. Neumann, P. Ganschow, A. Bazhin, M. Guba, J. Werner, M. Angele
- 10.1155/2019/7407190
- 2019
- J Oncol. 2019; 2019: 7407190.
16 de abr. de 2024 · Metastasis is the major cause of death in patients with colorectal cancer 1. The most common metastasis sites of colorectal cancer are the liver, followed by the lung, lymph node, and...
Among people diagnosed with metastatic colorectal cancer, approximately 70% to 75% of patients survive beyond 1 year, 30% to 35% beyond 3 years, and fewer than 20% beyond 5 years from diagnosis. The primary treatment for unresectable metastatic CRC is systemic therapy (cytotoxic chemotherapy, biologic therapy such as antibodies to cellular ...
